APLT Stock Discussion
Applied Therapeutics, Inc. Description
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Cardiomyopathy Retinopathy Myopathy Peripheral Neuropathy Preclinical Stage Product Stage Products Diabetic Peripheral Neuropathy Lactose Novel Products Preclinical Stage Products
Recent Comments
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
- ZealousTrout235 on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
- TraderMike on Market Recap for Tuesday, May 21, 2024
- CharmingMole371 on Market Recap for Tuesday, May 21, 2024
- TraderMike on IZM
From the Blog
Featured Articles